Hepatitis B

World Hepatitis Summit 2024 Convenes in Lisbon

Retrieved on: 
Donnerstag, April 4, 2024
Vaccination, Summit, WHO, Diagnosis, WHA, Viral hepatitis, ECDC, Friends, Policy, WHS, Family, Treatment, Private sector, Hepatitis B, COVID-19, Hepatitis, Vaccine

The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment

Key Points: 
  • The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment
    LONDON, Apr 4, 2024 - (ACN Newswire) - The World Hepatitis Summit (WHS) 2024 convenes in Lisbon from 9 - 11 April and will bring together global experts to discuss the latest advances in hepatitis prevention, diagnosis and treatment.
  • At the Summit, the World Hepatitis Alliance (WHA) and The European Centre for Disease Prevention and Control (ECDC) will present findings from a first-of-its-kind report examining levels of stigma and discrimination surrounding people living with hepatitis in Europe.
  • The report finds that half (50%) of those living with hepatitis B and C struggle to tell people about their hepatitis.
  • On the opening day of the Summit, WHO will release its 2024 Global Hepatitis Report.

UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine

Retrieved on: 
Freitag, Mai 10, 2024
Infection, Vaccination, University, Pelvic inflammatory disease, Bangladesh Technical Education Board, Molecular genetics, Rutgers University, Zhong, Mouse, Chlamydia, Food, Tissue, Infertility, Texas Biomedical Research Institute, University of Texas System, Doctor of Philosophy, Research, Vaccine, IND, NIAID, Disease, GI, Investigational New Drug, Gastrointestinal tract, DVM, Microbiology, MPH, Immunology, Vertically transmitted infection, HPV, Workforce, Hepatitis B, SAN, Hepatitis A

SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.

Key Points: 
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio) will direct a team of researchers to investigate a novel oral vaccine for chlamydia, the most reported sexually transmitted disease, with funding from the National Institutes of Health.
  • SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.
  • The UT Health San Antonio-led study of a novel oral vaccine that could protect against chlamydia infection is being funded through a cooperative agreements research project grant, known as a U01 grant.
  • Back in 2022, UT Health San Antonio was granted an exclusive global license to allow Ohio biopharmaceutical company Blue Water Vaccines Inc. to develop Zhong's findings into an oral vaccine for chlamydia.

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, Probability, Gilead Sciences, Food, Pembrolizumab, OPSCC, Partnership, IND, Roche, ASCO, Arenavirus, PRIME, Patient, EMA, Lung, Hepatitis B, HIV, Clinical trial, Annual general meeting, Food and Drug Administration, HBV, Pharmaceutical industry

The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.

Key Points: 
  • The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.
  • Effective April 25, 2024, HOOKIPA regained full control of the associated intellectual property portfolio and has full collaboration and licensing rights for this program.
  • HOOKIPA received FDA clearance of its IND application in the fourth quarter of 2023 and expects to initiate a Phase 1 clinical trial of HB-500 in people with HIV in the second quarter of 2024.
  • On January 29, 2024, HOOKIPA provided an update on its business priorities and oncology partnership programs.

Blue Faery Continues Its Love Your Liver Campaign During Asian American and Pacific Islander Heritage Month

Retrieved on: 
Dienstag, Mai 7, 2024
Education, Asian Americans, Hepatitis B, Fairy, Risk, Communication, Hepatocellular carcinoma, White Americans, Disease, HCC, Love, EST, Liver cancer, Prevalence, Dietary supplement

BIRMINGHAM, Ala., May 7, 2024 /PRNewswire/ -- Love Your Liver helps raise awareness about liver cancer risk factors in the Asian American community as they are twice as likely to develop the disease compared with White Americans. Liver cancer continues to be one of the greatest health disparities faced by Asian Americans due to the high prevalence of chronic hepatitis B infection within this community. Chronic hepatitis B is a leading risk factor for hepatocellular carcinoma (HCC), the most common type of liver cancer.

Key Points: 
  • BIRMINGHAM, Ala., May 7, 2024 /PRNewswire/ -- Love Your Liver helps raise awareness about liver cancer risk factors in the Asian American community as they are twice as likely to develop the disease compared with White Americans.
  • Liver cancer continues to be one of the greatest health disparities faced by Asian Americans due to the high prevalence of chronic hepatitis B infection within this community.
  • Chronic hepatitis B is a leading risk factor for hepatocellular carcinoma (HCC), the most common type of liver cancer.
  • Love Your Liver delivers culturally relevant education about liver cancer risk factors, liver cancer surveillance, and treatments while offering hope.

VBI Vaccines Reports Full Year 2023 Financial Results

Retrieved on: 
Dienstag, April 16, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Sale, Net, GAAP, MLE, Walmart, Pharmacy, Green Book, Government, Hepatitis B vaccine, Green, Prison, Research and development, Partnership, Control arm, GBM, Vaccine, Administration, Disease, Exercise, Patient, Carmustine, CAD, VBI, Hepatitis B, Messenger, Bank statement, Israeli new shekel, Internationalized domain name, Growth, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
  • Revenues, net: Revenues, net for the full year 2023 were $8.7 million as compared to $1.1 million for the same period in 2022.
  • Cost of Revenues: Cost of revenues was $12.5 million for the full year 2023 as compared to $11.3 million in 2022.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

Beckman Coulter's DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global

Retrieved on: 
Dienstag, April 16, 2024
Infection, HBsAg, Congress, WHO, Hepatitis B, Laboratory, World Health Organization, Hepatitis, Blood, DirectX, ESCMID, DXS, Disease, Senior, Patient, Analyser, Access, Cirrhosis, Hepatitis B virus, Serum, Beckman Coulter, Diagnosis, Chemistry, Liver cancer, Plasma, HBV, Vaccine

Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.

Key Points: 
  • Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.
  • Detection of the viral surface antigen (HBsAg) in serum or plasma indicates an infection caused by hepatitis B virus (HBV).
  • Building on the strengths and global success of the DxI 9000 Analyzer, Beckman Coulter is elevating efficiency and confidence for hepatitis testing.
  • According to Kathleen Orland, Senior Vice President, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics, "By launching these new hepatitis assays on our DxI 9000 Analyzer, we can deliver exceptional quality.

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Retrieved on: 
Dienstag, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, MRI, Weakness, Cell, Hepatitis B, Disease, Infection, Magnetic resonance imaging, Cirrhosis, Patient, Committee, Weight loss, Knowledge, PET, Neoplasm, Abdomen, Tissue, Regulation, Cancer, EMA, IRIS, Hepatocellular carcinoma, Woman, Nausea, European, COMP, Sponsor, European Commission, Safety, Pain, Molecular imaging, Marketing, Swelling, Liver, Medicine, Pharmaceutical industry

Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of hepatocellular carcinoma, 21/03/2016 Withdrawn

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Freitag, März 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning

Retrieved on: 
Dienstag, März 19, 2024
CD4, CDO, CD8, CBO, Hepatitis B, Disease, Janssen Pharmaceuticals, Death, Vaccine

His initial focus will be on the company’s candidate vaccine to treat chronic Hepatitis B and shape the future AstriVax vaccine pipeline.

Key Points: 
  • His initial focus will be on the company’s candidate vaccine to treat chronic Hepatitis B and shape the future AstriVax vaccine pipeline.
  • Leuven, Belgium, March 19, 2024 – AstriVax is pleased to welcome Dr. Gregory Fanning as its Chief Business Officer.
  • Dr. Fanning further strengthens the company’s top-notch leadership team, joining CEO and co-founder Dr. Hanne Callewaert, CTO Dr. Wilfried Dalemans, CDO Dr. Mathieu Peeters, and CFO Barbara Freitag.
  • The cure for this disease is likely to come from combining the AstriVax approach with that of several other companies.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, März 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.